Aptevo Therapeutics EPS Ratio 2011-2026 | APVO

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Aptevo Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-87.3	-31.5 K	-2.32 K	1.57	-6.07	-5.23	-13.9	-2.39	0.33	-5.55	-2.93	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.57	-31.5 K	-3.08 K

Quarterly EPS Ratio Aptevo Therapeutics

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-6.41	-2.23	-8.4	-4.39	-	-358	-1.24 K	-368	-	-22.2	-54	17.4	-	-1.5	5.58	-1.55	-	-1.43	-1.75	-1.64	-	-2.1	-2.1	0.89	-	-0.16	-4.14	-7.64	-	-0.55	-0.58	-0.63	-	1.77	-0.53	-0.48	-0.74	-3.55	-0.63	-0.64	-0.88	-0.63	-0.88	-0.54	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
17.4	-1.24 K	-57.5

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Autolus Therapeutics plc AUTL	-1.08	$ 1.7	3.03 %	$ 452 M	Britain
Happiness Biotech Group Limited HAPP	0.75	-	1.35 %	$ 17.8 M	China
Compugen Ltd. CGEN	0.38	$ 2.8	7.28 %	$ 262 M	Israel
AgeX Therapeutics AGE	-1.91	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	1.43	$ 1.61	2.55 %	$ 189 M	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	1.51	-	2.54 %	$ 160 B	France
BioNTech SE BNTX	-4.7	$ 92.14	1.33 %	$ 22.3 B	Germany
AstraZeneca PLC AZN	6.6	-	-	$ 96.9 B	Britain
Athira Pharma ATHA	-24.7	-	-	$ 269 M	USA
CRISPR Therapeutics AG CRSP	-6.47	$ 50.36	0.92 %	$ 4.53 B	Schweiz
BiondVax Pharmaceuticals Ltd. BVXV	-0.07	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	-0.037	-	-	$ 4.9 B	Britain
Galera Therapeutics GRTX	0.64	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	-0.0001	-	-18.52 %	$ 27.3 M	Britain
Affimed N.V. AFMD	-7.09	-	-34.95 %	$ 21.5 M	Germany
Enlivex Therapeutics Ltd. ENLV	27	$ 0.72	-0.37 %	$ 32.9 M	Israel
Esperion Therapeutics ESPR	-0.11	$ 3.13	-	$ 651 M	USA
Eton Pharmaceuticals ETON	-0.17	$ 32.59	-6.89 %	$ 877 M	USA
Checkmate Pharmaceuticals CMPI	-2.84	-	-	$ 231 M	USA
Forte Biosciences FBRX	-4.71	$ 21.59	-1.86 %	$ 280 M	USA
Celyad Oncology SA CYAD	-1.81	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	-1.42	-	-7.31 %	$ 87 M	USA
Generation Bio Co. GBIO	-1.98	-	-	$ 344 M	USA
IMV IMV	-4.55	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Cyclacel Pharmaceuticals CYCCP	-6.45	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	-1.5	-	-	$ 384 M	Britain
Gracell Biotechnologies GRCL	-1.8	-	-	$ 3.37 B	China
Anika Therapeutics ANIK	-0.76	$ 14.88	-0.93 %	$ 213 M	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	-3.27	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-1.57	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	-5.97	$ 3.4	-1.16 %	$ 5.6 M	Israel
Aptose Biosciences APTO	-10.4	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-0.96	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	-1.77	-	-0.23 %	$ 916 M	USA
InflaRx N.V. IFRX	-0.68	$ 2.61	5.67 %	$ 176 M	Germany
AlloVir ALVR	-2.85	-	4.14 %	$ 49.1 M	USA